HLA Analysis in Autoimmune Encephalitis and Related Disorders: Part II

Launched by HOSPICES CIVILS DE LYON · Mar 29, 2021

Keywords

ClinConnect Summary

This clinical trial, titled "HLA Analysis in Autoimmune Encephalitis and Related Disorders: Part II," is studying autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS). Autoimmune encephalitis involves inflammation in the brain that can lead to memory issues, confusion, and seizures, while PNS are neurological problems that can arise as a result of cancer. The researchers are particularly interested in understanding the genetic factors, specifically a part of our genes called HLA, that might influence why some people develop these conditions while others do not, even if they have similar health backgrounds.

To participate in this trial, individuals must have specific antibodies present in their blood or spinal fluid and show symptoms that match these antibodies based on existing research. For those with PNS, there must also be a diagnosis of cancer that aligns with the detected antibodies. Participants can expect to contribute to important research that could help identify genetic factors linked to these conditions, potentially leading to better understanding and treatment options in the future. The trial is currently recruiting participants of all genders, aged 65 to 74.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Presence of well-characterized antibodies in serum or cerebrospinal fluid;
• • Clinical picture compatible with the detected antibody based on the literature;
• • For PNS, cancer detected and compatible with the detected antibody based on the literature
• Exclusion Criteria:
• • Absence of complete clinicobiological data.
• • Incongruences between antibody-clinics or antibody-cancer